Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Insmed is set to challenge the Duchenne muscular dystrophy (DMD) treatment space with its innovative gene therapy asset, INS1201.

AbbVie and Simcere Zaiming have announced an option-to-license agreement for the development of an investigational drug candidate, SIM0500.

Incyte told JP Morgan attendees of plans for four launches in 2025, beginning with its FDA-approved Niktimvo for chronic GVHD.

Eight people have likely died from an outbreak of Marburg virus disease (MVD) in a northwestern region of Tanzania, according to the WHO.

Acadia Pharmaceuticals has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for trofinetide ...

Scaling personalized therapies brings unique logistical challenges. Unlike mass-market drugs, these treatments require highly specific materials, stringent cold chain logistics and real-time ...

J&J will protect the branded anti-interleukin (IL)-12/23 biologic Stelara against sales erosion from biosimilars.

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.

Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round to progress CAR-T cell therapy pipeline.

Additionally, Daiichi Sankyo has partnered with MSD in a $22bn deal to advance ADCs targeting HER3, B7-H3, and CDH6. Each therapy in this pipeline utilises Daiichi Sankyo’s DXd technology. Enhertu and ...

Spain’s Almirall has announced strategic plans at the 43rd JP Morgan Healthcare Conference based on expected double-digit growth within the dermatological area for Almirall’s psoriasis and atopic ...